We conclude that PR‐PFD demonstrated statistically significant efficacy in reducing noninvasive markers of liver fibrosis and improving biological tests associated with liver function (albumin, bilirubin, Child–Pugh, and MELD scores). This evidence concerns the gene ALB and Hepatic fibrosis.